Xuan Bai Cheng Qi formula as an adjuvant treatment of acute exacerbation of chronic obstructive pulmonary disease of the syndrome type phlegm-heat obstructing the lungs: a multicenter, randomized, double-blind, placebo-controlled clinical trial

Table 5 Lung function measurements in Xuan Bai Cheng Qi and control groups before and after 10-day treatment

Lung function^a	XBCQ^b			Control^b			Treatment effect^d(95% CI; P value)
	Day 1 (Baseline)	Day 10 (End)	Mean D^c	Day 1 (Baseline)	Day 10 (End)	Mean D^c
FEV₁ (liters)
FAS (122,122)	1.18 (0.41)	1.44 (0.49)	0.24 (0.29)	1.19 (0.40)	1.29 (0.47)	0.10 (0.31)	0.14 (0.06, 0.22; < .001)
PPS (111,118)	1.20 (0.42)	1.44 (0.49)	0.24 (0.29)	1.19 (0.39)	1.29 (0.47)	0.10 (0.31)	0.13 (0.06, 0.21; .001)
FVC (liters)
FAS (122,122)	2.16 (0.62)	2.40 (0.67)	0.23 (0.38)	2.10 (0.58)	2.17 (0.62)	0.08 (0.48)	0.17 (0.06, 0.28; .002)
PPS (111,118)	2.17 (0.60)	2.40 (0.65)	0.23 (0.38)	2.11 (0.57)	2.19 (0.60)	0.08 (0.48)	0.16 (0.05, 0.27; .004)
FEV₁ % pred
FAS (122,122)	51.54 (19.49)	62.39 (19.57)	10.59 (11.76)	52.13 (19.17)	55.35 (20.59)	3.22 (10.53)	7.33 (4.58, 10.07; < .001)
PPS (111,118)	52.60 (19.74)	63.38 (19.36)	10.49 (11.84)	52.17 (19.27)	55.56 (22.68)	3.39 (10.50)	7.20 (4.37,10.03; < .001)

Abbreviations: CI confidence interval, COPD chronic obstructive pulmonary disease, FEV ₁ forced expiratory volume in one second, FEV ₁ % pred FEV₁ percentage of predicted value, FVC forced vital capacity, GOLD Global Initiative for Chronic Obstructive Lung Disease, Mean D mean difference, XBCQ Xuan Bai Cheng Qi.
^aFAS population was 122 in the XBCQ group and 122 in the control group; PPS population was 111 in the XBCQ group and 118 in the control group.
^bData presented as mean (SD).
^c P < .01: Change between pre-treatment and post-treatment (within group difference by paired t-test).
^dCovariance analysis estimate with 95% confidence interval for difference.

ISSN: 2662-7671